Reference (year) | No. of patients | Method | Mutation frequencies | Region | Prognostic value |
---|---|---|---|---|---|
[2] Gao J., et al. (2011) | 273 | Direct sequencing | KRAS (38.5%); BRAF (5.1%) | Chinese | Â |
[24] Li H.T., et al. (2011) | 200 | Pyrosequencing | KRAS (31.5%); BRAF (7.0%); PIK3CA (12.5%) | Chinese | KRAS and PIK3CA bi-mutations were more likely to develop liver metastases. |
[25] Shen H., et al. (2011) | 118 | Pyrosequencing | KRAS (34.7%); BRAF (1.7%) | Chinese | Â |
[26] Liou J.M., et al. (2011) | 314 | Direct sequencing | KRAS (20.7%); BRAF (3.8%) | Taiwan | BRAF mutation was associated with worse overall survival. |
[27] Mao C., et al. (2012) | 69 | Direct sequencing | KRAS (43.9%); BRAF (25.4%); PIK3CA (8.2%) | Chinese | Â |
[28] Hsieh L.L., et al. (2012) | 182 | Direct sequencing & HRM | KRAS (33.5%); BRAF (1.1%); PIK3CA (7.1%) | Taiwan | Â |
[29] Zhu Y.F., et al. (2012) | 60 | Direct sequencing | PIK3CA (21.6%) | Chinese | High PI3K expression was associated with CRC metastases. |
[30] Li Z., et al. (2012) | 78 | Direct sequencing | KRAS (33.3%) | Chinese | KRAS mutations were associated with poor survival and liver metastasis. |
[31] Shen Y., et al. (2013) | 676 | Direct sequencing | KRAS (35.9%); BRAF (6.96%); PIK3CA (9.9%) | Chinese | Â |
[32] Pu X., et al. (2013) | 115 | Direct sequencing | KRAS (32.2%); BRAF (3.5%) | Chinese | Â |
[33] Wang J., et al. (2013) | 574 | Direct sequencing | KRAS (34.2%) | Chinese | Â |
[34] Chang Y.S., et al. (2013) | 165 | HRM | KRAS (36.97%); BRAF (4.24%) | Taiwan | KRAS mutation was associated with poor survival. |